RJA
RXRX icon

Raymond James & Associates’s Recursion Pharmaceuticals RXRX Stock Holding History

Raymond James & Associates’s Portfolio RXRX Stock Details RXRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-74,905
Closed -$562K – 4087
2024
Q2 		$562K Buy
74,905
+37,259
+99% +$325K ﹤0.01% 3001
2024
Q1 		$375K Buy
+37,646
New +$419K ﹤0.01% 3245
2023
Q4 		– Sell
-69,188
Closed -$529K – 3932
2023
Q3 		$529K Buy
+69,188
New +$690K ﹤0.01% 2854

Other funds holding RXRX

AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
MIC
Mubadala Investment Company Abu Dhabi, United Arab Emirates $20.5B AUM 19.39% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
KA
Kinnevik AB Stockholm, Sweden $65.6M AUM 25.95% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return

Raymond James & Associates's RXRX Position: Q3 2024 in Review

Raymond James & Associates sold out of Recursion Pharmaceuticals (RXRX) in Q3 2024, closing a stake of 74,905 shares — an estimated $562K sold.

Raymond James & Associates first reported a position in RXRX in Q3 2023 and held it in 3 quarters. The position peaked at $562K in Q2 2024. 267 funds tracked by Wall St. Rank hold RXRX as of Q3 2024.

  • Raymond James & Associates reported no remaining Recursion Pharmaceuticals position as of Q3 2024 after selling out during the quarter.
  • Raymond James & Associates sold 74,905 Recursion Pharmaceuticals shares in Q3 2024, an estimated $562K.
  • Raymond James & Associates first reported a position in Recursion Pharmaceuticals in Q3 2023 and held it in 3 quarters.
  • Raymond James & Associates's Recursion Pharmaceuticals position peaked at $562K in Q2 2024.
  • 267 funds tracked by Wall St. Rank held Recursion Pharmaceuticals as of Q3 2024.

Based on Raymond James & Associates's 13F filing for Q3 2024, filed 18 Oct 2024.